Biomarker Guided Discharge of Heart Failure Patients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorOttawa Heart Institute Research Corporation

About this trial

This is a multi-centre, single blind, randomized study. Patients admitted to hospital with acute decompensated heart failure will be randomized to biomarker guided discharge algorithm vs usual care in a 2:1 ratio. NTproBNP and other biomarkers will be measured within 24 hours of admission. The NTproBNP results will be used to further stratify participants randomized to the biomarker guided group into lower and medium to higher risk pathways. Biomarkers will be repeated after 2-3 days and again prior to discharge. Specific care pathways will be followed for each of the lower risk and medium-higher risk groups. Biomarkers will be repeated 30 days post discharge. Participants will be followed with a phone call at 3 months and return for a follow up visit at 6 months post discharge for outcome evaluation.

Eligibility criteria

Qualifiers

Patients admitted to hospital with a primary diagnosis of acute decompensated heart failure, compatible with the modified Framingham criteria

Disqualifiers

Patient unable to provide blood samples or cannot participate in follow-up

Patient with end stage organ failure

Kidney: creatinine >350 μmol/L or Estimated GFR ≤15 ml/min

Liver dysfunction: liver function test >2.5 times normal

Trial design

Treatments tested in this trial

  • Biomarker guided discharge algorithm

Treatment groups

750 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Ottawa Heart Institute Research Corporation

Lead sponsor

Genome Canada

Collaborator

Roche Diagnostics GmbH

Collaborator